Position in TRVI
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,510,612
-$1,316,308 QoQ
Shares Held
80,998
-65.8% QoQ
Ownership
0.057%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
#91
of 216 holders
Holding Since
Jun 2022
17 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in TRVI Over Time
Shares Held
Position Value (USD)
Derivatives in TRVI
reported options exposure · as of Dec 31, 2025CallValue
$83,884
CallShares
6,700
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026J. Goldman & Co LP holds $154,729,761 across 52 Biotechnology names. TRVI ranks #27 (1.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | COGT |
Cogent Biosciences, Inc.
|
637,994 | $24,690,367 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
38,698 | $11,649,258 | |
| 3 | CAPR |
Capricor Therapeutics, Inc.
|
427,321 | $10,289,889 | |
| 4 | MGTX |
MeiraGTx Holdings plc
|
601,972 | $8,132,641 | |
| 5 | ARDX |
Ardelyx, Inc.
|
1,579,828 | $8,057,122 | |
| 6 | URGN |
UroGen Pharma Ltd.
|
212,775 | $7,830,120 | |
| 7 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
12,311 | $6,115,243 | |
| 8 | ELVN |
Enliven Therapeutics, Inc.
|
112,129 | $5,690,546 |
All Filings in TRVI
Export CSV
22 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,510,612 | 80,998 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $2,826,920 | 236,959 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $5,563,349 | 444,357 | Shares | Sole | 2026-02-17 | |
| 2025-12-31 | $83,884 | 6,700 | Call | Sole | 2026-02-17 | |
| 2025-09-30 | $7,254,174 | 792,806 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $5,355,666 | 979,098 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $1,264,963 | 201,107 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $3,708 | 900 | Put | Sole | 2025-02-14 | |
| 2024-12-31 | $2,214,949 | 537,609 | Shares | Sole | 2025-02-14 | |
| 2024-12-31 | $736,656 | 178,800 | Call | Sole | 2025-02-14 | |
| 2024-09-30 | $3,006 | 900 | Put | Sole | 2024-11-14 | |
| 2024-09-30 | $497,382 | 148,917 | Shares | Sole | 2024-11-14 | |
| 2024-09-30 | $411,488 | 123,200 | Call | Sole | 2024-11-14 | |
| 2024-06-30 | $443,772 | 148,917 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $475,661 | 137,873 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $184,749 | 137,873 | Shares | Sole | 2024-02-14 | |
| 2023-09-30 | $300,563 | 137,873 | Shares | Sole | 2023-11-14 | |
| 2023-06-30 | $329,516 | 137,873 | Shares | Sole | 2023-08-14 | |
| 2023-03-31 | $164,997 | 89,188 | Shares | Sole | 2023-05-15 | |
| 2022-12-31 | $172,132 | 89,188 | Shares | Sole | 2023-02-14 | |
| 2022-09-30 | $137,349 | 89,188 | Shares | Sole | 2022-11-14 | |
| 2022-06-30 | $379,350 | 135,000 | Shares | Sole | 2022-08-15 | |
| No filing history on record for this holder in this stock. | ||||||